The Laboratory Role in anti-TNF Biological Therapy Era.
TNF
adalimumab
anti-TNF drugs
certolizumab
immunogenicity
Journal
Immunological investigations
ISSN: 1532-4311
Titre abrégé: Immunol Invest
Pays: England
ID NLM: 8504629
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
pubmed:
13
7
2019
medline:
6
11
2020
entrez:
13
7
2019
Statut:
ppublish
Résumé
Along years, the advent of biological therapy widely modified treatment of rheumatic diseases and other disorders. However, many agents may elicit in anti-drug antibodies (ADAbs) upon consecutive infusions, with a loss of response. For the right strategy of a personalized medicine, the therapeutic monitoring of TNF-α inhibitors and ADAbs represents an important effort in diagnostic-therapeutic pathway, to improve overall patient management and favoring an appropriate clinical approach. A raising number of diagnostic tests have been designed to elucidate the efficacy and/or safety of a specific drug or class of drugs for a targeted patient's group. Our paper reviewed the current understanding of the immunogenicity of biological drugs employed in the treatment of inflammatory diseases underlying the laboratory role.
Identifiants
pubmed: 31298595
doi: 10.1080/08820139.2019.1637434
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Biomarkers
0
Tumor Necrosis Factor Inhibitors
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM